Junevity raised $10M in seed funding led by Goldcrest Capital and Godfrey Capital to enhance its RESET platform for developing cell reset therapeutics for longevity.

Feb 13, 2025•10 months ago

Amount Raised

$10 Million

Round Type

seed

San FranciscoBiotechnologyHealth Care

Investors

Godfrey CapitalGoldcrest Capital

Description

Junevity, a biotechnology company focused on extending lifespan and healthspan, announced $10 million in seed funding. The funding will be used to enhance the RESET platform and develop therapeutic candidates targeting Type 2 diabetes, obesity, and frailty.

Company Information

Company

Junevity

Location

San Francisco, California, United States

About

Junevity is a longevity biotechnology company developing Cell Reset therapeutics. The RESET Platform is the first to use large-scale human data and AI to develop novel siRNA therapeutics targeting transcription factors. Founded out of UCSF in 2023, Junevity’s mission is to extend human lifespan and healthspan.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends